1. Advanced diffuse histiocytic lymphoma, a potentially curable disease;DeVita;Lancet,1975
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma;Fisher;N Engl J Med,1993
3. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin’s lymphoma;Linch;Br J Cancer,1996
4. Pfreundschuh M, Truemper L, Kloess M, et al: 2-weekly vs. 3-weekly CHOP with and without etoposide for patients > 60 years of age with aggressive non-Hodgkin’s lymphoma (NHL): Results of the completed NHL-B-2 trial of the DSHNHL. Blood 100:774a, 2002a (abstr)
5. Pfreundschuh M, Truemper L, Schmits R, et al: 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin’s lymphoma: Results of the completed NHL-B-1 Trial of the DSHNHL. Blood 100:92a, 2002b (abstr)